The Producers Life Insurance coverage Firm raised its stake in shares of Quest Diagnostics Included (NYSE:DGX – Get Rating) by 3.3% within the third quarter, in accordance with the corporate in its most up-to-date disclosure with the Securities and Change Fee (SEC). The fund owned 120,167 shares of the medical analysis firm’s inventory after buying an extra 3,866 shares throughout the interval. The Producers Life Insurance coverage Firm owned roughly 0.11% of Quest Diagnostics price $14,799,000 as of its most up-to-date SEC submitting.
→ The Next Big Crisis Is Here (From Porter & Firm)
Different institutional buyers have additionally made adjustments to their positions within the firm. Wagner Wealth Administration LLC bought a brand new place in shares of Quest Diagnostics within the second quarter valued at roughly $27,000. Chilton Capital Administration LLC bought a brand new place in shares of Quest Diagnostics within the second quarter valued at roughly $36,000. Larson Monetary Group LLC boosted its stake in shares of Quest Diagnostics by 1,096.6% within the second quarter. Larson Monetary Group LLC now owns 347 shares of the medical analysis firm’s inventory valued at $46,000 after buying an extra 318 shares throughout the interval. Eagle Bay Advisors LLC bought a brand new place in shares of Quest Diagnostics within the second quarter valued at roughly $47,000. Lastly, Parkside Monetary Financial institution & Belief boosted its stake in shares of Quest Diagnostics by 136.2% within the first quarter. Parkside Monetary Financial institution & Belief now owns 411 shares of the medical analysis firm’s inventory valued at $56,000 after buying an extra 237 shares throughout the interval. 88.79% of the inventory is presently owned by institutional buyers and hedge funds.
Quest Diagnostics Inventory Efficiency
Shares of Quest Diagnostics stock opened at $144.91 on Thursday. The agency’s fifty day easy shifting common is $150.60 and its 200-day easy shifting common is $139.39. The inventory has a market capitalization of $16.50 billion, a price-to-earnings ratio of 14.25 and a beta of 0.98. Quest Diagnostics Included has a 12 month low of $120.40 and a 12 month excessive of $158.34. The corporate has a debt-to-equity ratio of 0.63, a present ratio of 1.46 and a fast ratio of 1.34.
Quest Diagnostics Declares Dividend
The agency additionally just lately introduced a quarterly dividend, which can be paid on Wednesday, February 1st. Stockholders of report on Wednesday, January 18th can be issued a $0.66 dividend. The ex-dividend date of this dividend is Tuesday, January seventeenth. This represents a $2.64 dividend on an annualized foundation and a dividend yield of 1.82%. Quest Diagnostics’s payout ratio is 25.96%.
Analyst Upgrades and Downgrades
DGX has been the topic of a number of latest analysis reviews. Mizuho raised their value goal on shares of Quest Diagnostics from $160.00 to $165.00 and gave the corporate a “purchase” ranking in a analysis be aware on Wednesday, December 14th. Deutsche Financial institution Aktiengesellschaft lifted their value goal on shares of Quest Diagnostics from $129.00 to $140.00 and gave the inventory a “maintain” ranking in a analysis be aware on Friday, October twenty first. Evercore ISI began protection on shares of Quest Diagnostics in a analysis be aware on Monday. They issued an “inline” ranking and a $159.00 value goal for the corporate. Citigroup downgraded shares of Quest Diagnostics from a “impartial” ranking to a “promote” ranking and decreased their value goal for the inventory from $145.00 to $125.00 in a analysis be aware on Thursday, November seventeenth. Lastly, StockNews.com upgraded shares of Quest Diagnostics from a “maintain” ranking to a “purchase” ranking in a analysis be aware on Tuesday, January tenth. One equities analysis analyst has rated the inventory with a promote ranking, six have assigned a maintain ranking and 4 have assigned a purchase ranking to the corporate. In response to MarketBeat.com, the inventory has a median ranking of “Maintain” and a median value goal of $149.90.
Insider Exercise
In different information, Director Timothy M. Ring offered 2,000 shares of Quest Diagnostics inventory in a transaction on Tuesday, November 1st. The shares had been offered at a median value of $144.06, for a complete worth of $288,120.00. Following the transaction, the director now immediately owns 24,149 shares of the corporate’s inventory, valued at roughly $3,478,904.94. The sale was disclosed in a submitting with the Securities & Change Fee, which is accessible by this hyperlink. In different Quest Diagnostics information, Director Timothy M. Ring offered 2,025 shares of the enterprise’s inventory in a transaction on Thursday, December 1st. The shares had been offered at a median value of $152.50, for a complete worth of $308,812.50. Following the transaction, the director now immediately owns 24,149 shares of the corporate’s inventory, valued at roughly $3,682,722.50. The sale was disclosed in a submitting with the Securities & Change Fee, which is accessible by this link. Additionally, Director Timothy M. Ring offered 2,000 shares of the enterprise’s inventory in a transaction on Tuesday, November 1st. The shares had been offered at a median value of $144.06, for a complete transaction of $288,120.00. Following the completion of the transaction, the director now immediately owns 24,149 shares within the firm, valued at $3,478,904.94. The disclosure for this sale will be discovered here. Insiders have offered 44,790 shares of firm inventory valued at $6,678,255 within the final ninety days. 1.70% of the inventory is presently owned by firm insiders.
Quest Diagnostics Firm Profile
Quest Diagnostics, Inc engages within the provision of diagnostic testing, info and providers. It operates by the Diagnostic Info Providers (DIS) and All Different segments. The DIS section presents diagnostic info providers to sufferers, clinicians, hospitals, well being plans, and employers.
Additional Studying
This on the spot information alert was generated by narrative science expertise and monetary information from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you contemplate Quest Diagnostics, you may wish to hear this.
MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they suggest to their purchasers every day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Quest Diagnostics wasn’t on the record.
Whereas Quest Diagnostics presently has a “Maintain” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.
